Healthcare Business

Akcea and Ionis Pharma Win Big in Midstage Cardiovascular Disease Study

Akcea Therapeutics Inc. (NASDAQ: AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ: IONS) shares made a solid gain on Monday after the companies announced positive top-line data for a midstage trial in ...
Read Full Story »

Kodiak Sciences Announces Potential Pricing for IPO

Kodiak Sciences has registered an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company expects to price its 9.0 million ...
Read Full Story »

What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments

There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch ...
Read Full Story »

Jefferies Biotech Growth Picks Have Big Upside Potential

Increasingly, the companies on Wall Street that we cover are starting to agree that while the future's still bright for the U.S. economy, the future may be one of stock market ...
Read Full Story »

Why Amarin Shares Are Exploding

Amarin Corp. PLC (NASDAQ: AMRN) shares absolutely skyrocketed on Monday after the company announced top-line results from the Vascepa cardiovascular (CV) outcomes trial, REDUCE-IT. Needless to say, the results were ...
Read Full Story »

What the FDA Has to Say About Acadia Pharma’s Parkinson’s Treatment

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) shares made a handy gain to close out the week after the company announced that the U.S. Food and Drug Administration (FDA) completed a post-marketing ...
Read Full Story »

Why JPMorgan Is So Bullish on Novavax

Novavax Inc. (NASDAQ: NVAX) is one of those small-cap biotech stocks that has the hallmarks of a rags-or-riches company. It might be worth more money down the road than can ...
Read Full Story »

Can GTx Make It Past This Enobosarm Study?

GTx Inc. (NASDAQ: GTXI) shares were absolutely crushed on Friday after the company announced results from its midstage trial in post-menopausal women with stress urinary incontinence. Unfortunately, the Phase 2 ...
Read Full Story »

Stifel Has Red-Hot Biotech Stocks to Buy With Huge Upside Potential

Needless to say, the biotech world has had a volatile 18 months. Some of the biggest and the best companies, many of which trade cheaper than big pharmaceutical companies, are ...
Read Full Story »

Elanco Explodes Into the Market in IPO

Elanco Animal Health Inc. (NYSE: ELAN) made a strong entrance to the market on Thursday. Shares went out at $32.25, well above the high end of the expected price range ...
Read Full Story »

How Adverum Bio Is Winning With FDA Update

Adverum Biotechnologies Inc. (NASDAQ: ADVM) shares made a handy gain on Thursday after the company announced a key update from the U.S. Food and Drug Administration (FDA). The FDA granted ...
Read Full Story »

Should AbbVie Be More Concerned About Its California Case for Humira?

AbbVie Inc. (NYSE: ABBV) shares took a dip on Wednesday after it was announced that the pharmaceutical giant would be facing a lawsuit from the California Department of Insurance in ...
Read Full Story »

Clovis Finally Faces the Music for Fraudulent Lung Cancer Drug Results

Clovis Oncology Inc. (NASDAQ: CLVS) shares might not be showing it now, but the company is facing some heat from the U.S. Securities and Exchange Commission (SEC). The company, its ...
Read Full Story »

Why Tilray Shares Are Getting Even Higher

Tilray Inc. (NASDAQ: TLRY) continued its incredible rally with shares up massively on Tuesday after the U.S. Drug Enforcement Administration granted approval for the company to import a cannabinoid study ...
Read Full Story »

Why Viking Therapeutics Fatty Liver Study More Than Doubled Shares

Viking Therapeutics Inc. (NASDAQ: VKTX) shares more than doubled on Tuesday after the company announced results from its midstage non-alcoholic fatty liver disease (NAFLD) trial. Specifically, Viking announced positive topline ...
Read Full Story »